Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor
Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.
You may also be interested in...
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
CEO Kevin Ali talked to Scrip about his plans for Organon, ahead of the spinout from Merck & Co. Women's health will be the top priority.